These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10229624)

  • 21. Application of validated QSAR models of D1 dopaminergic antagonists for database mining.
    Oloff S; Mailman RB; Tropsha A
    J Med Chem; 2005 Nov; 48(23):7322-32. PubMed ID: 16279792
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
    Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
    J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alkylamides as inducers of human leukemia cell differentiation: a quantitative structure-activity relationship study using comparative molecular field analysis.
    Harpalani AD; Snyder SW; Subramanyam B; Egorin MJ; Callery PS
    Cancer Res; 1993 Feb; 53(4):766-71. PubMed ID: 8428356
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative structure-activity relationship modeling of dopamine D(1) antagonists using comparative molecular field analysis, genetic algorithms-partial least-squares, and K nearest neighbor methods.
    Hoffman B; Cho SJ; Zheng W; Wyrick S; Nichols DE; Mailman RB; Tropsha A
    J Med Chem; 1999 Aug; 42(17):3217-26. PubMed ID: 10464009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of the structural requirements of the receptor-binding affinity of diphenolic azoles to estrogen receptors alpha and beta by three-dimensional quantitative structure-activity relationship and structure-activity relationship analysis.
    Demyttenaere-Kovatcheva A; Cronin MT; Benfenati E; Roncaglioni A; Lopiparo E
    J Med Chem; 2005 Dec; 48(24):7628-36. PubMed ID: 16302803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of ordinal CoMFA by ridge logistic partial least squares.
    Ohgaru T; Shimizu R; Okamoto K; Kawashita N; Kawase M; Shirakuni Y; Nishikiori R; Takagi T
    J Chem Inf Model; 2008 Apr; 48(4):910-7. PubMed ID: 18338844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of variable docking conditions and scoring functions on corresponding protein-aligned comparative molecular field analysis models constructed from diverse human protein tyrosine phosphatase 1B inhibitors.
    Taha MO; AlDamen MA
    J Med Chem; 2005 Dec; 48(25):8016-34. PubMed ID: 16335926
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative molecular field analysis of a series of paclitaxel analogues.
    Zhu Q; Guo Z; Huang N; Wang M; Chu F
    J Med Chem; 1997 Dec; 40(26):4319-28. PubMed ID: 9435901
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CoMFA study of novel phenyl ring-substituted 3alpha-(diphenylmethoxy)tropane analogues at the dopamine transporter.
    Newman AH; Izenwasser S; Robarge MJ; Kline RH
    J Med Chem; 1999 Sep; 42(18):3502-9. PubMed ID: 10479283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative molecular field analysis (CoMFA) model using a large diverse set of natural, synthetic and environmental chemicals for binding to the androgen receptor.
    Hong H; Fang H; Xie Q; Perkins R; Sheehan DM; Tong W
    SAR QSAR Environ Res; 2003; 14(5-6):373-88. PubMed ID: 14758981
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CoMFA on the melanogenesis inhibitory activity of alkyl-3,4-dihydroxybenzoate, N-alkyl-3,4-dihydroxybenzamide analogues, and prediction of higher active compounds.
    Kim SJ; Myung PK; Sung ND
    Arch Pharm Res; 2008 Dec; 31(12):1540-6. PubMed ID: 19099221
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 3D-QSAR studies on the inhibitors of AP-1 and NF-kappaB mediated transcriptional activation.
    Qin J; Liu H; Li J; Ren Y; Yao X; Liu M
    Eur J Med Chem; 2009 Jul; 44(7):2888-95. PubMed ID: 19128859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 3D-QSAR design of novel antiepileptic sulfamides.
    Gavernet L; Dominguez Cabrera MJ; Bruno-Blanch LE; Estiú GL
    Bioorg Med Chem; 2007 Feb; 15(3):1556-67. PubMed ID: 17158052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 3D-QSAR study of bis-azaaromatic quaternary ammonium analogs at the blood-brain barrier choline transporter.
    Geldenhuys WJ; Lockman PR; Nguyen TH; Van der Schyf CJ; Crooks PA; Dwoskin LP; Allen DD
    Bioorg Med Chem; 2005 Jul; 13(13):4253-61. PubMed ID: 15878282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-dimensional quantitative structure: activity relationship studies on diverse structural classes of HIV-1 integrase inhibitors using CoMFA and CoMSIA.
    Nunthaboot N; Tonmunphean S; Parasuk V; Wolschann P; Kokpol S
    Eur J Med Chem; 2006 Dec; 41(12):1359-72. PubMed ID: 17002889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3D-QSAR study of 20 (S)-camptothecin analogs.
    Lu AJ; Zhang ZS; Zheng MY; Zou HJ; Luo XM; Jiang HL
    Acta Pharmacol Sin; 2007 Feb; 28(2):307-14. PubMed ID: 17241535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Voltage-gated Na+ channel ligands and ATP: relative molecular similarity and implications for channel function.
    Williams WR
    J Pharm Pharmacol; 2006 Sep; 58(9):1235-41. PubMed ID: 16945182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3D-QSAR studies of farnesyltransferase inhibitors: a comparative molecular field analysis approach.
    Puntambekar D; Giridhar R; Yadav MR
    Bioorg Med Chem Lett; 2006 Apr; 16(7):1821-7. PubMed ID: 16455255
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 3D-QSAR studies of Checkpoint Kinase Weel inhibitors based on molecular docking, CoMFA and CoMSIA.
    Yi P; Fang X; Qiu M
    Eur J Med Chem; 2008 May; 43(5):925-38. PubMed ID: 17698256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3D-QSAR study of ring-substituted quinoline class of anti-tuberculosis agents.
    Nayyar A; Malde A; Jain R; Coutinho E
    Bioorg Med Chem; 2006 Feb; 14(3):847-56. PubMed ID: 16214351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.